appliednano_10q-033112.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 10-Q
 
x Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended March 31, 2012
 
¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
COMMISSION FILE NO. 1-11602
 
APPLIED NANOTECH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

TEXAS
76-0273345
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
  
3006 Longhorn Blvd., Suite 107
Austin, Texas
78758
(Address of principal executive offices)
(Zip Code)
  
(512) 339-5020
(Registrant's telephone number, including area code)
  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x
Yes
o
No

Indicate by check mark whether the registrant  has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.

x
Yes
o
No
  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definition of “accelerated filer”, “large accelerated filer”, and “smaller reporting company” in rule 12b-2 of the Act.

Large Accelerated Filer o
Accelerated Filer o
Non-accelerated Filer o
Smaller Reporting Company x
  
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o
Yes
x
No
  
As of April 30, 2012, the registrant had 119,137,919 shares of common stock, par value $.001 per share, issued and outstanding.


 
 
 
 
 
APPLIED NANOTECH HOLDINGS, INC.
INDEX

 
 
Page
   
Part I.  Financial Information
 
   
 
Item 1.  Financial Statements
 
     
 
Consolidated Balance Sheets--March 31, 2012 and December 31, 2011
3
     
 
Consolidated Statements of Operations--Three Months Ended March 31, 2012 and 2011
4
     
 
Consolidated Statements of Cash Flows--Three Months Ended March 31, 2012 and 2011
5
     
 
Notes to Consolidated Financial Statements
6
     
 
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
8
     
 
Item 3.  Quantitative and Qualitative Disclosures about Market Risk
12
     
 
Item 4.  Controls and Procedures
12
     
Part II.  Other Information
 
   
 
Item 1.  Legal Proceedings
13
     
 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds
13
     
 
Item 6.  Exhibits
13
     
Signatures
14
   
 
2

 
 
PART I.  FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

ASSETS
 
(Unaudited)
March 31,
2012
   
December 31,
2011
 
Current assets:
           
Cash and cash equivalents
  $ 2,172,935     $ 3,071,783  
Accounts receivable, trade – net of allowance for doubtful accounts
    550,989       839,863  
Prepaid expenses and other current assets
    117,970       153,021  
                 
Total current assets
    2,841,894       4,064,667  
                 
Property and equipment, net
    352,993       303,055  
Other assets
    28,591       28,745  
Total assets
  $ 3,223,478     $ 4,396,467  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
                 
Current liabilities:
               
Accounts payable
  $ 486,772     $ 324,333  
Convertible notes payable
    1,540,782        
Obligations under capital lease
    56,084       40,701  
Accrued liabilities
    421,371       379,675  
Deposits and deferred revenue
    200,000       200,000  
                 
Total current liabilities
    2,705,009       944,709  
                 
Obligations under capital lease, long-term
    52,652       48,559  
                 
Convertible notes payable
          1,486,510  
                 
Total liabilities
    2,757,661       2,479,778  
                 
Commitments and contingencies
           
                 
Stockholders' equity:
               
Preferred stock, $1.00 par value, 2,000,000 shares authorized;
            No shares issued and outstanding
           
Common stock, $.00l par value, 160,000,000 shares authorized,
            119,137,919 and 118,915,698 shares issued and outstanding at
            March 31, 2012 and December 31, 2011, respectively
    119,138       118,916  
Additional paid-in capital
    114,810,131       114,654,026  
Accumulated deficit
    (114,463,452 )     (112,856,253 )
                 
Total stockholders' equity
    465,817       1,916,689  
                 
Total liabilities and stockholders' equity
  $ 3,223,478     $ 4,396,467  
 
 
See notes to consolidated financial statements.
   
 
3

 
 
APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    For the Three Months Ended
March 31,
 
   
2012
   
2011
 
Revenues
           
Government contracts
  $ 416,166     $ 1,251,092  
Contract research
    67,212       548,790  
License fees and royalties
    177,300       1,140  
Other
    116,458       135,959  
Total revenues
    777,136       1,936,981  
                 
Research and development
    1,353,266       1,601,734  
Selling, general and administrative expenses
    942,004       817,555  
                 
Operating costs and expenses
    2,295,270       2,419,289  
                 
                 
Loss from operations
    (1,518,134 )     (482,308 )
                 
Other income (expense), net
               
Interest expense
    (89,911 )     (132,431 )
Interest income
    846       942  
                 
Loss before taxes
    (1,607,199 )     (613,797 )
                 
Provision for taxes
           
                 
Net loss
  $ (1,607,199 )   $ (613,797 )
Loss per share
               
                 
Basic and Diluted 
  $ (0.01 )   $ (0.01 )
Weighted average shares outstanding
               
                 
Basic and Diluted 
    119,061,376       110,759,903  
 
 
See notes to consolidated financial statements.
  
 
4

 
  
APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
   
For the Three Months Ended
March 31,
 
   
2012
   
2011
 
Cash flows from operating activities:
           
Net loss
  $ (1,607,199 )   $ (613,797 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization expense
    26,121       14,883  
Amortization of discount on debt
    54,272       93,211  
Stock based compensation expense
    96,327       196,360  
Changes in assets and liabilities:
               
Accounts receivable, trade
    288,874       (344,671 )
Prepaid expenses and other assets
    35,205       (61,708 )
Accounts payable and accrued liabilities
    264,135       (169,618 )
Deposits and deferred revenue
          206,910  
                 
Total adjustments
    764,934       (64,633 )
                 
Net cash used in operating activities
    (842,265 )     (678,430 )
                 
Cash flows from investing activities:
               
Capital expenditures
    (47,492 )     (8,508 )
Net cash used in investing activities
    (47,492 )     (8,508 )
                 
Cash flows from financing activities:
               
Proceeds from issuance of common stock
          2,526,314  
Repayment of capital lease obligations
    (9,091 )     (5,935 )
                 
Net cash provided by (used in) financing activities
    (9,091 )     2,520,379  
                 
Net increase (decrease) in cash and cash equivalents
    (898,848 )     1,833,441  
                 
Cash and cash equivalents, beginning of period
    3,071,783       2,732,570  
                 
Cash and cash equivalents, end of period
  $ 2,172,935     $ 4,566,011  
   
 
See notes to consolidated financial statements.
  
 
5

 
 
APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

 
1.  Basis of Presentation
 
The consolidated financial statements of the Company for the three-month periods ended March 31, 2012 and 2011, have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the Company’s management, all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company as of March 31, 2012 and 2011, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet of the Company as of December 31, 2011, has been derived from the audited consolidated balance sheet of the Company as of that date.
 
Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as filed with the Securities and Exchange Commission.
  
The results of operations for the three-month period ended March 31, 2012, are not necessarily indicative of the results to be expected for the full year.
 
2.  Supplemental Cash Flow Information
 
Cash paid for interest for the three months ended March 31, 2012 and 2011, was $3,323 and $987, respectively. During the three months ended March 31, 2012 and 2011, the Company had non-cash transactions related to share based payments described in greater detail in Note 5, non-cash transactions related to the conversion of accounts payable into common stock described in greater detail in Note 4, and non-cash transactions related to the conversion of notes payable and related accrued interest into common stock that are described in greater detail in Note 3. The Company also had a capital lease transaction in the amount of $28,567 in the three months ended March 31, 2012.
 
3.  Notes Payable and Long-Term Debt
   
We issued convertible notes payable in 2009 and 2010. These notes bear interest at a rate of 8% and are due in 2012. The notes and resulting accrued interest are convertible into shares of our common stock at rates of $0.20 to $0.25 per share. The face amount of the notes due was $2,146,000, and we valued the conversion rights at $647,250, which was recorded as a discount at the time of issuance. This discount is being amortized to interest expense over the term of the note. $216,000 of these notes were issued to officers and directors of the Company. As of March 31, 2012, a total of $526,000 of these notes have been converted to common stock, leaving a remaining principal balance as of that date of $1,620,000. A total of $79,218 of unamortized discount remains to be amortized in future periods. During the quarter ended March 31, 2011, a total of $317,000 of principal and related accrued interest of $30,607 was converted into 1,724,996 shares of common stock. No notes were converted in the quarter ended March 31, 2012.
 
4.  Stockholders’ Equity
   
During the three months ended March 31, 2011, we issued 6,578,948 restricted shares of common stock and received proceeds of $2.5 million in an exempt offering under Regulation D of the Securities Act of 1933, and 107,587 shares for total proceeds of $26,314 in connection with the exercise of options by former employees. We also issued 157,895 shares of restricted common stock in payment of accounts payable in the amount of $60,000 during the same period, as well as 103,722 shares in connection with restricted stock payments to employees.  During the three months ended March 31, 2012, we issued 222,222 restricted shares of common stock related to the payment of $60,000 of trade payables  in an exempt offering under Regulation D of the Securities Act of 1933.   
  
 
6

 
 
APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
  
5.  Share-Based Payments
   
We use the fair value method to account for stock based compensation. We recorded $96,327 and $196,360 in compensation expense in the periods ended March 31, 2012 and 2011, respectively, related to options and restricted stock issued under our stock-based incentive compensation plans. This includes expense related to both options issued and committed, as well as unissued restricted stock  in the current year, and options issued in prior years for which the requisite service period for those options includes the current year. The fair value of these options was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. For options issued in 2012, the same approximate assumptions were used.
 
6.  Contingencies
 
Litigation
 
The Company is a defendant in minor lawsuits described in greater detail in its 2011 annual report on Form 10-K. The Company expects any potential eventual payment to have no material affect on the financial statements.
 
 
 
 
 
 
 
 
7

 
  
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following is management’s discussion and analysis of certain significant factors that have affected the Company’s financial position and operating results during the periods included in the accompanying consolidated financial statements.
 
FORWARD-LOOKING STATEMENTS
 
This Form 10-Q contains certain forward-looking statements that we believe are within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements, including the statements under "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding our strategy, future operations, future expectations or future estimates, financial position and objectives of management. Those statements in this Form 10-Q containing the words "believes," "anticipates," "plans," "expects" and similar expressions constitute forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on our current expectations and are subject to a number of risks, uncertainties and assumptions relating to our operations, results of operations, competitive factors, shifts in market demand and other risks and uncertainties.
 
Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate and actual results may differ from those indicated by the forward-looking statements included in this Form 10-Q.  In light of the significant uncertainties inherent in the forward-looking statements included in this Form 10-Q, you should not consider the inclusion of such information as a representation by us or anyone else that we will achieve such results. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
 
Three months ended March 31, 2012 and 2011
 
OVERVIEW
 
We are primarily a nanotechnology company engaged in the development of technologies, based principally on our intellectual property. We generate revenues by performing research services, licensing our technology, and selling products based on our technology. During all periods presented, our primary revenues were earned as a result of reimbursed research expenditures and licensing of our technology. As more fully discussed in our Annual Report on Form 10-K for the year ended December 31, 2011, we expect to incur significant additional research and development expenses in 2012 to further develop our technology. We are focused on commercializing our technology and obtaining sufficient revenue to cover our ongoing expenditures.
 
OUTLOOK
 
We expect our present cash balances, when combined with known and expected revenue sources, to enable us to operate through the end of 2012. However, our cash on hand is only adequate to allow us to operate through the end of September 2012.We expect to sign additional contracts during this time period which will extend that period further. This includes contracts we expected to sign in the first quarter that we now expect to sign in future quarters. We have also accelerated our spending on commercialization of our technology in March and April, which also causes us to use our cash more quickly. If we do not receive the expected revenue sources as quickly as anticipated, we may be required to cut back on our commercialization activities, or raise additional funding.
 
We have a plan to achieve profitability in 2012, and that plan anticipated a loss in the first quarter, which is expected to be offset by profits for the balance of the year. Since developing this plan, we have accelerated spending on commercialization activities that may make it difficult for us to achieve profitability this year. We also anticipate hiring additional sales resources in 2012 that would further increase our costs. A critical component of our plan is the receipt of additional revenues. These revenues must come from a variety of sources, including research revenues, license fees – either in the form of an upfront payment, or from ongoing royalties as a result of product sales by our licensees, and product sales by us.
  
 
8

 

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)
 
At the present time, there can be no assurance that we will achieve our plan for profitability in 2012, or that expected revenue sources will all occur as planned. It is not possible for us to achieve profitability without license fees or royalties at our present level of activity. In order to achieve profitability solely based on research revenues, our research revenue would have to more than double from our expected level for 2012, and the majority of the revenue would have to come from non-governmental sources. The mix of revenues received could also cause the revenues required to reach break-even to increase. If revenue producing projects require unanticipated expenses, or heavier than anticipated use of outside services and materials, we may be unable to achieve profitability at the expected level of revenues.  We believe that we have the ability to continue to obtain funding, if necessary, to enable us to continue operations until we reach profitability.  
 
Our plan is based on current development plans, current operating plans, the current regulatory environment, historical experience in the development of electronic products and general economic conditions. Changes could occur which would cause certain assumptions on which this plan is based to be no longer valid. If adequate funds are not available from operations, or other sources of financing, we may have to eliminate, or reduce substantially, expenditures for research and development, testing and production of its products, or obtain funds through arrangements with other entities that may require us to relinquish rights to certain of our technologies or products. Such results could materially and adversely affect us.
 
RECENT DEVELOPMENTS
 
During 2012 we have received new contracts with the U.S. government totaling approximately $1.4 million. These contracts, in addition to increasing our revenue backlog, will be of significant value in continued development of some of our high potential technologies, including our sensor technology and our thermal management material.
 
RECENT ACCOUNTING PRONOUNCEMENTS
 
There are no recent accounting pronouncements that we have not implemented that are expected to have a material impact on our financial statements.
  
 
9

 
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)
 
FINANCIAL CONDITION AND LIQUIDITY
 
Our cash position decreased during the period from approximately $3.1 million at December 31, 2011 to approximately $2.2 million at March 31, 2012.  This decrease in cash is primarily the result of cash used in operating activities.
 
Our operating activities used $842,265 of cash in the quarter ended March 31, 2012 (the “2012 Period”), as opposed to the cash used by operating activities of $678,430 in the quarter ended March 31, 2011 (the “2011 Period”). The cash used in both periods is primarily the result of the net loss during the periods as further discussed below in the “Results from Operations” section. In  addition to the net loss, in the 2012 Period, the cash used in operations was affected by changes in working capital items. The use of cash in the 2012 Period was reduced by collection of receivables from the prior period and by an increase in the amount of trade payables at the end of the period.
 
We would expect our cash used in, or provided by, operating activities to fluctuate in future quarters in 2012, depending on the timing of receipt of various items. We expect positive cash flow from operations in future quarters in 2012, but not necessarily in all quarters, as a result of increasing revenues, particularly license agreements, while expenses increase at a much lower rate.
 
We had cash used in financing activities of approximately $9,000 in the 2012 Period related to payments made on capital lease obligations. Our cash provided by financing activities was approximately $2.5 million in the 2011 Period. This was the result of issuing common stock to increase our cash balance and solidify our financial position.
 
We used an insignificant amount of cash related to the purchase of equipment in both periods. We expect cash used in investing activities to remain at relatively insignificant levels for the balance of 2012.
 
Historically, the principal source of our liquidity has been funds received from exempt offerings of common stock. Our current cash balance is relatively strong and our plan is to sign additional contracts so that we do not need to raise additional debt or equity in 2012 simply to support operations; however, in the event that we do need additional funds for strategic or commercialization purposes, we may seek to sell additional debt or equity securities. While we expect to be able to obtain any funds needed for operations, there can be no assurance that any of these financing alternatives can be arranged on commercially acceptable terms. We believe that our success in reaching profitability will be dependent on our patent portfolio and upon the viability of products using our technology and their acceptance in the marketplace, as well as our ability to obtain additional debt or equity financings in the future, if needed.
 
We expect to continue to incur substantial expenses for research, development  and commercialization activities. Further, we believe that certain products that may be developed by potential licensees of our technology may not be available for commercial sale or routine use for a period of one to two years. Others are expected to be available in 2012. While we would likely receive initial license payments, ongoing royalty streams related to some licenses may not be available until potential licensees have introduced products using our technology. Therefore, it is possible that the commercialization of our existing and proposed products may require additional capital in excess of our current funding. We do, however, have a plan to operate profitably in 2012 based on the receipt of research funding, license agreements, product sales, and other revenues. We are, however, accelerating spending on commercialization activities that may make it difficult for us to achieve profitability in 2012. Achievement of at least break-even would enable us to continue our research without seeking additional financing in the future.
 
Because the timing and receipt of revenues from product sales, or license and royalty agreements will be tied to the achievement of certain product development, testing and marketing objectives, which cannot be predicted with certainty, there may be substantial fluctuations in our results of operations. If revenues do not increase as rapidly as anticipated, or if product development and testing require more funding than anticipated, we may be required to curtail our operations or seek additional financing from other sources at some point in the future. The combined effect of the foregoing may prevent us from achieving sustained profitability for an extended period of time.
  
 
10

 
   
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)
 
RESULTS OF OPERATIONS
 
Our net loss for the 2012 Period was approximately $1.6 million, as compared with the net loss of approximately $600,000 for the 2011 Period. The reasons for the increased loss are discussed in more detail below.
 
Our revenues for the quarter ended March 31, 2012, totaled approximately $800,000, compared to approximately $1.9 million for the same quarter in 2011. The revenues in both periods were substantially all the result of reimbursed research expenditures. The majority of the revenues in both periods came from government sources, which is included in government contract revenue in the statement of operations. At the present stage of our development, significant conclusions cannot be drawn by comparing revenues from period to period; however, we would expect the quarterly revenue for the balance of 2012 to increase above the first quarter level in the majority of quarters. Our plan calls for targeted revenues of $8.9 million for 2012. Our business strategy is built on commercializing our technology through product sales and developing a royalty stream from licensing our intellectual property. To supplement this, we also seek funding from both governmental and private sources to help fund our research. Until we are able to develop a steady revenue stream from royalties, or product sales, our revenues will tend to fluctuate greatly from quarter to quarter. Our private research funding tends to come in large amounts at sporadic times.
 
We have a research revenue backlog of approximately $1.8 million as of March 31, 2012. We had a total research revenue backlog of approximately $3.0 million as of March 31, 2011, and a research revenue backlog of $2.3 million as of December 31, 2011. Our ability to perform continued research, or fulfill our backlog, should not require significant additional personnel; however, we do plan to increase this backlog significantly throughout 2012 and an increase in revenue levels may require additional personnel. We expect our revenue backlog to continue to support our current revenue levels.
 
We incurred research and development expenses of approximately $1.35 million for the 2012 Period, a decrease from the approximately $1.6 million incurred in the 2011 Period. This decrease in research expenses is a direct result of the decreased research revenue in the 2012 Period. We expect research and development expenditures to remain near the current level for the balance of 2012; however, significant new revenue producing research programs beyond those already identified could, however, cause research and development expenditures to increase further.
 
Our selling, general, and administrative expenses were approximately $942,000 for the 2012 Period, compared with approximately $817,000 for the 2011 Period. This increase in selling, general, and administrative expenses was primarily the result of increased selling expenses related to commercialization activities.
 
Our interest income is insignificant in both periods. Our interest income results from the investment of excess funds in short term interest bearing instruments, primarily certificates of deposit, commercial paper, and money market funds. We expect our interest income to remain at insignificant levels for the balance of 2012. Our interest expense, which is primarily the result of our convertible notes payable, decreased in the 2012 Period. This interest expense includes both the stated interest rate on the debt and the amortization of the discount associated with the notes. The interest expense decreased because a portion of the notes were converted in 2011.We would expect our interest expense to remain at levels for the second and third quarters of 2012. We expect the remaining notes to be converted in the third quarter of 2012, when they become due.
   
 
11

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We do not use any derivative financial instruments for hedging, speculative, or trading purposes. Our exposure to market risk is currently immaterial.
 
 
ITEM 4.  CONTROLS AND PROCEDURES
 
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this report (the "Evaluation Date"). Based upon this evaluation, our principal executive officer and principal financial officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the material information required to be included in our Securities and Exchange Commission ("SEC") reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to the Company, including, our consolidated subsidiaries, and was made known to them by others within those entities, particularly during the period when this report was being prepared.
 
In addition, there were no significant changes in our internal controls over financial reporting or in other factors that could significantly affect these controls subsequent to the Evaluation Date. We have not identified any material weaknesses in our internal controls, and therefore, no corrective actions were taken.
  
 
12

 
 
PART II.  OTHER INFORMATION
 
ITEM 1.  LEGAL PROCEEDINGS
 
None
 
 
ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
From January 1, 2012 through March 31, 2012, we issued 222,222 restricted shares of common stock in payment of an accounts payable of $60,000 in an exempt offering under Regulation D of the Securities Act of 1933.
 
 
ITEM 6.  EXHIBITS
 
(a)  Exhibits: See Index to Exhibits on page 15 for a descriptive response to this item.
 
 
 
 
 
13

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
APPLIED NANOTECH HOLDINGS, INC.
(Registrant)
   
Date:  May 1, 2012 
 
 
/s/ Douglas P. Baker
Douglas P. Baker
Chief Executive Officer, Chief Financial Officer
(Principal Executive Officer, Principal Financial
Officer, and Principal Accounting Officer)
 
 
 
 
 
14

 
 
INDEX TO EXHIBITS
 
The following documents are filed as part of this Report:
  
Exhibit
  Description
     
11
 
Computation of (Loss) Per Common Share
     
31.1
 
Rule 13a-14(a)/15d-14(a) Certificate of Douglas P. Baker
     
32.1
 
Section 1350 Certificate of Douglas P. Baker
 
 
 
 
 
 
 
15

appliednano_10q-ex11.htm

EXHIBIT 11
 
Applied Nanotech Holdings, Inc.
 
Computation of Income (Loss) Per Share
 
   
Three Months ended March 31,
 
   
2012
   
2011
 
             
Computation of loss per common share:
           
             
Net loss applicable to common shares
  $ (1,607,199 )   $ (613,797 )
                 
Weighted average number of common shares
    119,061,376       110,759,903  
                 
Net income (loss) per common share
  $ (0.01 )   $ (0.01 )
                 
Computation of income ( loss ) per common share assuming full dilution**
               

** No computation of diluted loss per common share is included for any period because such computation results in an antidilutive loss per common share.
appliednano_10q-ex3101.htm

EXHIBIT 31.1
 
Certificate of Chief Executive and Chief Financial Officer
Pursuant to Rule 13a-14(a)/15d-14(a)
 
I, Douglas P. Baker, certify that:
 
1.    I have reviewed this quarterly report on Form 10-Q for the quarter ended March 31, 2012, of Applied Nanotech Holdings, Inc. (“APNT”);
 
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations and cash flows of APNT as of, and for, the periods presented in this report.
 
4.    APNT’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting as defined in the Exchange Act Rules 13a – 15(f) and 15d – 15(f) for APNT and have:
 
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to APNT, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)    Evaluated the effectiveness of APNT’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)    Disclosed in this report any change in APNT’s internal control over financial reporting that occurred during APNT’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, APNT’s internal control over financial reporting; and
 
5.    APNT’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to APNT’s auditors and the audit committee of APNT’s board of directors:
 
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect APNT’s ability to record, process, summarize and report financial information; and
 
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in APNT’s internal control over financial reporting.
 
Date: May 1, 2012
 
/s/ Douglas P. Baker
Douglas P. Baker
Chief Executive and Chief Financial Officer
appliednano_10q-ex3201.htm

EXHIBIT 32.1
 
 
Section 1350 Certification of Chief Financial Officer
 
 
In connection with the quarterly report of Applied Nanotech Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas P, Baker, the Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
1. The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
 
2. The information contained in this Report fairly presents, in all material respects, the financial conditions and results of operations of the Company as of the dates and for the periods expressed in the report.

Date: May 1, 2012
/s/ Douglas P. Baker
Douglas P. Baker
Chief Executive Officer and
Chief Financial Officer